Loss of PIM1 correlates with progression and prognosis of salivary adenoid cystic carcinoma (SACC)

Jiajie Xu1†, Xin Zhu2†, Qingling Li3, Chao Chen1, Zhenying Guo4, Zhuo Tan1, Chuanming Zheng1 and Minghua Ge1*

Abstract

Background: Increasing evidence indicates that PIM1 is a potential prognostic marker and target for cancer treatment but its precise mechanisms of action remain to be determined in salivary adenoid cystic carcinoma (SACC). This study aims to decipher the prognostic and mechanistic role of PIM1 in progression of SACC cells and tumor tissues.

Methods: A SACC cell line (ACC-M) was transfected with shRNA plasmids targeting the PIM1 gene. The expression levels of PIM1, RUNX3 and p21 were measured by quantitative real-time PCR and western blot. Subcellular translocalization of RUNX3 and p21 proteins was assessed using immunofluorescence, and cell cycle phase was quantified using flow cytometry. A total of 97 SACC patients were retrospectively analyzed by clinicopathologic characteristics and survival outcomes.

Results: After down-regulation of PIM1 in ACC-M cells, RUNX3 and p21 proteins were translocated from cytoplasm to nucleus, with a decrease of p21 expression and increase of G0/G1 phase cells. PIM1 and RUNX3 levels show a distinct covariance. PIM1 is associated with T-status, lymph node involvement, nerve invasion, and distant metastasis in SACC tissues. Patients with low PIM1 level had a better outcome than those with higher PIM1 level.

Conclusions: PIM1 is multifunctional in ACC-M cells and it serves as a neoteric therapeutic target and potential prognostic marker for SACC patients.

Keywords: Salivary adenoid cystic carcinoma, PIM1, p21, RUNX3, Short hairpin RNA

Background

Adenoid cystic carcinoma (ACC), a common salivary gland cancer subtype, accounts for 22% of salivary gland malignancies in humans [1]. Salivary adenoid cystic carcinoma (SACC) is characterized by highly aggressive nerve and vessel infiltration, high rate of recurrence, and frequent metastasis to lung [2]. Local recurrence and distant metastasis resulting from tumor insensitivity to radiotherapy and chemotherapy are the primary causes for SACC therapy failure [3]. The main treatment includes local resection with additional radiation therapy and chemotherapy, a treatment regimen that has not changed over many years. Lack of novel and effective treatments to inhibit SACC progression is still a major hurdle to overcoming this deadly disease. It is important to further understand SACC progression and the molecular mechanisms driving SACC.

PIM1, identified as a preferential integration site for moloney murine leukemia virus to induce T-lymphomas in mice [4], belongs to a small group of kinases with two homologues (PIM2 and PIM3). PIM1 is an oncogene and its encoded product exhibits serine/threonine kinase activity [5]. In several human cancer types, including T-and B-cell leukemia and lymphomas, the overexpression of PIM1 inhibits apoptosis, promotes proliferation, and prevents differentiation and maturation [6]. PIM1 kinase promotes cell cycle progression and proliferation...
by phosphorylating and enhancing the phosphatase activity of G0 phase regulator Cdc25A and G2/M phase regulator Cdc25C [7].

PIM1 is thought to be constitutively active without the need for posttranslational modification; the level of its kinase activity therefore depends on the absolute amount of protein in cells [8]. The preferential phosphorylation consensus sequence of PIM1 is (Arg/Lys) 4-X-Ser/Thr-XV [9, 10]. Proteins phosphorylated by PIM1 include p21, p100, cdc25A phosphatase, HP1, PAP1, PTP-U2S, NFATc1, TFAF2/SNX6 and nuclear mitotic apparatus protein (NuMA) [11–19]. Previous studies demonstrated that overexpression of PIM1 could inhibit apoptosis of tumor cells by regulating the cell cycle [20, 21]. Inhibition of PIM1 expression suppresses growth of tumor cells [22]. Although PIM1 is a known oncogene in various human cancers, its potential role as a therapeutic target has not been explored in SACC. In the present study, the expression of PIM1 gene was inhibited in ACC-M cells by constructing short hairpin RNA (shRNA) against PIM1 to understand its role in SACC.

One potential mechanism for PIM1 in SACC cells is phosphorylation of p21. It is known that the p21 gene encodes a 21kD protein which binds and inhibits a wide range of cyclin/CDK complexes and predominantly blocks G1/S phase cell cycle transition. Also, p21 interacts with proliferating cell nuclear antigen (PCNA) in the nucleus to inhibit DNA replication [23, 24]. More exactly, the C-terminal portion of p21 is phosphorylated at Thr145 by PIM1 and this phosphorylation event results in p21 subcellular localization [11]. A study by Zhang et al. implies that PIM1 might influence cell cycle progression by affecting p21 [5].

The RUNX3 tumor suppressor gene encodes a transcription factor that regulates lineage-specific gene expression in developmental processes and is involved in the formation of multiple cancers. The expression level of RUNX3 can be a prognostic indicator in variety of malignancies [25]. Our previous study demonstrated that RUNX3 protein is mainly expressed in nucleus and cytoplasm of acinous cells and ductal cells in normal salivary gland, but only in cytoplasm of tumor cells in SACC. RUNX3 cytoplasmic expression levels may significantly affect prognosis [26]. The expression of RUNX3 protein could be a potential biomarker for diagnosis and prognosis of SACCs. In SACC cells, PIM1 may alter subcellular localization of RUNX3 by phosphorylation, which has been demonstrated in HEK 293 cells [27]. In addition, RUNX3 is the upstream regulator of p21 expression. It is clear that the tumor suppressor activity of RUNX3 is at least partly associated with its ability to induce p21 expression [28].

PIM1 is involved in multiple cellular activities and it is likely that PIM1 has more unidentified substrates. As we know, PIM1 regulates the subcellular localization of p21 [11] and RUNX3 [27], which may lead to cellular apoptosis in SACC. Increasing evidence indicates that PIM1 is a potential target for cancer treatment but its precise mechanisms of action remain to be determined in SACC. In the present study, we describe various modes of action that PIM1 exerts in SACC cells (ACC-M) in vitro. These results may assist in development of PIM1 inhibitors to treat SACC.

Materials and methods

Construction of pGPU6/GFP/Neo-shRNA carrier
The plasmid pGPU6/GFP/Neo was purchased from GenePharma and the negative control plasmid (no homology to disrupt the sequence) was provided by GenePharma. We designed and synthesized four pairs of shRNA oligos (Shanghai Invitrogen Biotechnology Co., Ltd, China). Annealed shRNA oligos were ligated into the pGPU6/GFP/neo vector before transformation into E. coli. We selected 3 clones from each plate for growth in LB liquid medium containing 50 mg/L kanamycin overnight at 37 °C. Clones were analyzed by sequencing (Shanghai Invitrogen Biotechnology Co., Ltd, China). The four target sites for PIM1 shRNA are shown below:

PIM1-shRNA-1, 5'-AACATCCTTATCGACCTCAAT CGCG-3';
PIM1-shRNA-2, 5'-GTCTCTTCAGAATGTCAGCA T-3';
PIM1-shRNA-3, 5'-GGATCCTGCTGTATGATATG G-3';
PIM1-shRNA-4, 5'-GGGTTTCTCCGCGTCATT AG-3'.

Transfection of ACC-M cells

ACC-M was purchased from the Cell Bank for Type Culture Collection, Chinese Academy of Sciences (Beijing, China), and cultured in RPMI-1640 medium (Gibco) supplemented with fetal calf serum (10% Huclone), penicillin (100 U/mL) and streptomycin (100 μg/mL). ACC-M cells were seeded in a 6-well culture plate at a density of 1 × 10^5 cells/well. After 24 h, transfection complexes were assembled as follows: 4 μg of pGPU6/GFP/Neo-shRNA plasmid or negative control plasmid was resolved in 400 μL RPMI 1640 medium (serum-free and antibiotic-free). To this, 9 μL Lipofectamine™ 2000 transfection reagent was added, thoroughly mixed, and allowed to stand at room temperature for 10 min to form transfection complexes. The transfection mix was added to
Reverse transcriptase (RT)-PCR and quantitative real-time PCR (qRT-PCR)

RT-PCR and qRT-PCR were performed as described previously [29]. The following primers were used:

- PIM1 forward, 5′-TGTGCTGGAGAATATCTTGGAA-3′ and reverse, 5′-AGGTGGCTCAGCCTTGGG-3′ (size: 160 bp);
- p21 forward, 5′-GGAGACCTCAGGTTGAGA-3′ and reverse, 5′-GAGAGATACAGCCTGGGG-3′ (size: 77 bp);
- RUNX3 forward, 5′-CCAAGGGCCTCAGGAATCTG-3′ and reverse, 5′-TCTCCGTGAGGTTGGG-3′ (size: 83 bp);
- GAPDH forward, 5′-CATGAGAAGTATGACAACAG-3′ and reverse, 5′-AGTCCCTTCCAGTACACAAAGT-3′ (size: 113 bp).

After PCR amplification, dissociation of SYBR Green-labeled cDNA (melt curve analysis) was carried out to affirm that there were no nonspecific PCR products. 

$2^{-\Delta\Delta Ct}$ method was performed to analyze the relative quantification of transcript expression.

Detection of protein expression by western blot

Cells were harvested at 80% confluence and lysed by suspension in RIPA lysis buffer followed by gentle sonication. Protein lysates (20 μg) were separated on 8% SDS polyacrylamide gel by electrophoresis and transferred to PVDF membrane (Millipore). Membranes were then blocked in PBS/Tween (PBS with 5% non-fat powered milk and 0.05% Tween 20) at room temperature for 2 h. The blot was then incubated with affinity-purified rabbit anti-PIM1 (Novus NBP1-40501, 1:500) overnight. The immunoreactivity was visualized using the Pierce Super Signal West Pico Systems (Pierce).

Cell cycle analysis

ACC-M cells (1 × 10^6/mL) in logarithmic growth phase were plated in 6-well plates and transfected as described above. The cells were fixed with ice-cold 70% ethanol at −20 °C for 12–24 h. The cells were collected after centrifugation and resuspended in 500 μL of PBS buffer containing RNase A (the final concentration of RNase A was 0.25 mg/mL) and incubated at 37 °C for 30 min. Five microliter PI was added and incubated for 30 min at room temperature in dark. Data were acquired by flow cytometry (FACS Calibur, Becton–Dickinson).

Immunofluorescence staining analysis

ACC-M cells were transfected as described. After 48 h, cells were washed twice with PBS. Following fixation with 4% paraformaldehyde (15 min, 37 °C), cells were washed three times in PBS and then permeabilized with 0.1% Triton X-100 in PBS for 2 min at room temperature. Samples were blocked with 3% BSA and 0.05% Tween 20 in PBS (blocking solution) for 30 min at room temperature and then incubated overnight at 4 °C with primary antibodies (PIM1, Novus NBP1-40501, 1:200; p21, Novus NBP200-303, 1:200; RUNX3, Novus NBP1-46694, 1:200), respectively. For the immunofluorescence staining method, cells were incubated with secondary antibodies (1 μg/mL), DyLight 488 AffiniPure Goat Anti-Mouse IgG (H+L) (EarthOx) at 1:100 for Novus NB200-303 and DyLight 594 AffiniPure Goat Anti-Rabbit IgG (H+L) (EarthOx) at 1:100 for Novus NB1-40501 and Novus NB1-46694. There secondary antibodies were conjugated to Alexa-488 green fluorescence (Molecular Probes, Eugene, OR). Cells were counterstained with 4′,6-diamidino-2-phenylindole (DAPI, Sigma). Samples were visualized by confocal microscopy at 63× magnification.

Tissue specimens

Ninety-seven patients with histopathologically proven SACC in Zhejiang Cancer Hospital between July 2002 and July 2014 were recruited for this study. The study was approved by the Ethics Committee of Zhejiang Cancer Hospital. All patients have signed the informed consent.

Immunohistochemistry

Paraffin-embedded tissues were cut for 4 μm sections mounted on glass slides (Mats-unami,MS-coated glass) and dried overnight at 37 °C. After deparaffinization, antigen retrieval in 0.01 M citrate buffer, and inactivation of endogenous peroxidase activity in 3% H₂O₂/methanol, the slides were incubated with antibody for PIM1 (Novus NB1-40501, 1:200) and RUNX3 (Novus NB1-46694, 1:200) at 4 °C overnight. The immunoreactivity was visualized by using a streptavidin–biotin–peroxidase staining kit (Nichirei, Histofine Simple Stain Max PO Multi) and DAB solution (Nichirei, Simple Stain DAB). The results were presented as percentage of nucleus staining positive cells relative to total cells. The scores of staining results were given as negative and positive. In brief, IHC score was determined by combining staining frequency and intensity. In detail, the staining frequency score was defined as no cell stained scored as 0, 1–10% of cells stained as 1, 11–50% of cells stained as 2, 51–80% of cell stained as 3, and 81–100% of cell stained as 4. Staining
intensity score was rated on a scale of 0–3, with 0 for negative; 1 for weak; 2 for moderate; and 3 for strong staining. Theoretically, the scores could range from 0 to 12. An IHC score of 9–12 was considered as strong immunoreactivity, 5–8 as moderate, 1–4 as weak and 0 as completely negative. Sections in which the staining could not be well characterized were considered as equivocal. Staining was scored independently by two pathologists who were blinded to each other’s findings. All conflicting calls on scoring were adjudicated by a third individual. We used IHC score 5–12 for normal to high expression (positive) and 0–4 for no to low expression (negative).

Statistical analysis
SPSS 22.0 was used to perform one-way ANOVA for the discrepancy of three groups or more. The two-tailed Student’s t-test was used to detect any statistically significant difference between two groups. Associations between PIM1, RUNX3 levels, and clinicopathologic parameters were analyzed by using the χ² test or the Fisher exact test. Survival analysis was carried out by the Kaplan–Meier method and significant differences were assessed by means of the log-rank test. p values < 0.05 were considered to be statistically significant.

Results
Downregulation of PIM1 in ACC-M cells treated with pGPU6/GFP/Neo-shRNA
In this study, we used Lipofectamine™ 2000 reagent to optimize the transfection condition. The pGPU6/GFP/Neo-shRNA vector can express green fluorescent protein after being transfected into ACC-M cells. By fluorescence microscopy, we found that the total transfection rate was more than 70% after transfected for 48 h.

Both PIM1 mRNA and protein levels were significantly decreased in ACC-M cells after shRNA transfection. As shown in Fig. 1, real-time PCR results indicated that transcript levels of PIM1 in ACC-M cells were depleted by...
shRNA transfection ($p < 0.05$) in all interference groups. The PIM1-shRNA-3 transfection achieved the most effective knockdown of PIM1. Western blot analysis showed that the protein expression of PIM1 in ACC-M transfected with shRNA for 24 and 48 h was also decreased. PIM1-shRNA-3 and PIM1-shRNA-4 were most effective and thus used in the following experiments.

Effects of pGPU6/GFP/Neo-shRNA transfection on the expression of p21 and RUNX3
As shown in Fig. 2a, transcript levels of p21 were significantly decreased in ACC-M cells after transfection of shRNA targeting PIM1 ($p < 0.05$). There was no change in RUNX3 mRNA levels after PIM1 knockdown. Protein expression of p21 in shRNA transfected ACC-M cells was also decreased. There was no significant reduction of RUNX3 protein in the shRNA interference transfections versus the vector control group.

Cell cycle analysis of ACC-M cells after transient RNAi silencing of PIM1
Transfection of ACC-M cells with shRNA against PIM1 significantly disrupted the cell cycle. In the PIM1-shRNA-3 transfections, cells in G0/G1 stage increased from 42.3 to 57.2% ($p < 0.05$), while cells in G2/M stage and S stage decreased from 26.4 to 17.7% and 30.8 to 24.5%, respectively. Transfection with PIM1-shRNA-4 produced similar results; cells in G0/G1 stage increased from 42.3 to 60.5% ($p < 0.05$), while cells in G2/M stage and S stage decreased from 26.4 to 13.6% and 30.8 to 24.7%, respectively. These data indicated that shRNA transfection in ACC-M cells caused inhibition in the G1 phase, thus resulting in decreased numbers of cells in the S phase (Fig. 3).

PIM1 knockdown causing translocalization of p21 and RUNX3 from cytoplasm to nuclear
As shown in Fig. 4, p21 and RUNX3 are mainly located in the cytoplasm in the presence of PIM1. After transfection with shRNA against PIM1, p21 and RUNX3 staining is predominantly nuclear.

Correlation between PIM1 and RUNX3 protein levels in SACC tissues
PIM1 and RUNX3 immunohistochemical (IHC) staining in SACC tissues is shown in Fig. 5. PIM1 and RUNX3 positive ratios were 84.54% (82/97) and 18.56% (18/97), respectively. Table 1 showed a significant inverse correlation between the PIM1 and RUNX3 protein expression.

Correlation between the level of PIM1, RUNX3, and clinical characteristics in SACC tissues
We analyzed the correlation between PIM1 and RUNX3 expression in SACC tissues and clinicopathologic indexes. Table 2 shows that both PIM1 and RUNX3 levels were closely associated with T-status, lymph node involvement, nerve invasion, and distant metastasis ($p < 0.05$).

Survival analysis
Kaplan–Meier survival curves (Fig. 6) indicate that high PIM1 levels had an intimate association with survival of SACC patients ($p = 0.01$). Patients with low PIM1 levels had much better outcome than those with higher PIM1 levels.

Discussion
The PIM1 oncogene has been implicated in various human cancers including lymphomas, gastric, colorectal, and prostate carcinomas [30]. Highly conserved serine/threonine kinase activity encoded by PIM1 has been demonstrated to have an important role in
Fig. 3  Downregulation of PIM1 induces ACC-M cell cycle arrest in G0/G1 phase. ACC-M cells transfected with the indicated shRNA-PIM1 or with scrambled control duplex (shRNA-NC) were cultured for 48 h and the use of DNA dye PI generates characteristic cellular DNA content profiles. 

**a** The PIM1-shRNA transfected ACC-M cells caused inhibition of the G1 stage, histograms represent the percentage of ACC-M cells in G1, S, and G2 phases of the cell cycle 48 h after shRNA-transfection. 

**b** Table representing percentages of cells in G0/G1, S and G2/M phases of the cell cycle after indicated transfection (treatment). Blank: non-transfected normal cell sample; vector control: negative control group, PIM1-shRNA-3 and PIM1-shRNA-4 represent PIM1 knockdown.
regulating cell proliferation, differentiation, apoptosis, and tumorigenicity.

In this study, the pGPU6/GFP/Neo-shRNA was used as an optimized expression vector together with green fluorescent protein (GFP) reporter gene to deplete PIM1 levels in SACC cells. Using RNA interference technology, we successfully constructed shRNA recombinant plasmids targeting PIM1 gene expression. After transfection, silencing of PIM1 gene in ACC-M cells was evidenced by decreased PIM1 mRNA and protein expression. Silencing of the PIM1 gene caused ACC-M cell cycle arrest in G1 phase and decreased the proportion of cells in S phase.

Similar to other tumor types, interactions exist between oncogenes and tumor suppressor genes involved in the development and maintenance of SACC. Here, we propose a model wherein PIM1 kinase affects expression and subcellular localization of tumor suppressor genes in SACC. Our model is supported by data showing two suppressor genes, p21 and RUNX3, are affected by PIM1 kinase knockdown in ACC-M cells. The p21

![Fig. 4](image_url)
protein is one of the most studied inhibitors of cell cycle-dependent kinase (CDK). p21 arrests the cell cycle in G1 phase by inhibiting the CDK activity in G0 phase [31]. RUNX3 gene is a well-studied tumor suppressor gene, and it is a downstream transcription factor of transcription growth factor-β (TGF-β) signaling pathway. TGF-β can effectively inhibit cell growth and disruptions of the TGF-β signaling pathway can lead to a variety of tumors [32]. RUNX3, a MST (mammalian sterile 20-like) signaling pathway terminal effector, assisted by MST and SAV1, can induce cell apoptosis [33]. Early in 2006, a research team identified novel protein–protein interactions between the C-terminal of human RUNX3 and PIM1 using yeast two-hybrid technology [34]. Previous study has demonstrated that PIM1 can phosphorylate four Ser/Thr residues within the Runt domain and stabilize RUNX3 protein [27]. In SACC tissues, we found that there was a significant inverse correlation between the PIM1 and RUNX3 expression.

The present study indicated that the mRNA and protein expression of PIM1 and p21 was decreased in pGPU6/GFP/Neo-shRNA-PIM1 transfected cells, while the mRNA and protein expression of RUNX3 was not affected. The knockdown of PIM1 induced nuclear localization of p21 and RUNX3. The p21 and RUNX3 proteins are involved in multiple cellular functions, especially in cell differentiation and apoptosis. Most of these functions depend on the interaction of p21 and RUNX3 with associated proteins in distinct cellular compartments. The redistribution of p21 and RUNX3 in ACC-M cells may activate cellular apoptosis. Our data suggests that

| Variable | Patients (n = 97) | p-value |
|----------|------------------|---------|
| PIM1     | 15               | 82      | 0.000  |
| RUNX3    | 79               | 18      |        |

![Fig. 5 Immunohistochemical (IHC) staining of PIM1 and RUNX3 in SACC tissues (x400). A Negative PIM1 IHC staining in SACC tissues. B Positive PIM1 IHC staining in SACC tissues. C Negative RUNX3 IHC staining in SACC tissues. D Positive RUNX3 IHC staining in SACC tissues.](image-url)
silencing PIM1 regulates p21 and RUNX3 subcellular distribution and influences multiple cellular functions.

The IHC results show that a higher PIM1 and lower RUNX3 level is associated with advanced T-stage, lymph node involvement and nerve invasion that translates to aggressive tumor behavior. Importantly, other clinical features including gender, age, tumor location and histological grade type showed no correlation. Higher PIM1 levels are significantly associated with distant metastasis. This evidence suggests the important role of PIM1 in SACC, most likely mediated by RUNX3.

The short hairpin RNA expression vector for PIM1 silencing was successfully constructed, and pGPU6/GFP/Neo-shRNA-PIM1 could knockdown the expression of PIM1 gene and regulate the cell cycle. The tumor suppressors p21 and RUNX3 were affected by PIM1 kinase knockdown, which may provide a partial explanation for the pleiotropic effects of this multifunctional kinase. Our study indicates that PIM1 could be a potential prognostic marker for SACC and provides an experimental basis for SACC target therapy although the mechanism needs further elaboration and exploration. Therefore, more studies are needed in order to define mechanisms of PIM1 expression and function in SACC.

**Conclusions**

Our studies demonstrate that down regulation of PIM1 expression effectively decreases p21 expression and disrupts cell cycle. The subcellular re-localization of RUNX3 and p21 caused by PIM1 knockdown may partially explain diverse cellular functions of PIM1. PIM1 serves as a neoteric therapeutic target and potential prognostic marker for SACC patients.
Abbreviations
SACC: salivary adenoid cystic carcinoma; IHC: immunohistochemistry; GFP: green fluorescent protein; p21: p21CIP1/WAF1, RUNX3: run-related transcription factor 3, RT-PCR: real time quantitative polymerase chain reaction.

Authors’ contributions
JX, XX and MZH designed and supervised the experiments. JX, XX and YZW performed real-time PCR, cell cycle detection and FCM test. ZT, CC and CMZ carried out the western blot experiment. ZYG made the immunofluorescence staining analysis. JX and CC performed statistical analysis. JX and ZX drafted the manuscript. All authors read and approved the final manuscript.

Author details
1 Department of Head and Neck Surgery, Zhejiang Cancer Hospital, No. 38 Guangji Road, Hangzhou 310022, Zhejiang, China. 2 Zhejiang Cancer Research Institute, Hangzhou 310022, China. 3 Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou 310022, China. 4 Department of Pathology, Zhejiang Cancer Hospital, Hangzhou 310022, China.

Acknowledgements
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Availability of data and materials
Please contact the corresponding author for data requests.

Ethics approval and consent to participate
Informed consent was obtained from all individual participants included in the study.

Funding
This study was supported by the National Natural Science Foundation of China (Grant Number 81202127), the Zhejiang Medical and Health Science and Technology Plans (Grant Numbers 2012KYA031 and 2013KYB033) and the Zhejiang Provincial Natural Science Foundation (Grant Number LY16H160036).

Informed consent
Informed consent was obtained from all individual participants included in the study.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 1 November 2017    Accepted: 3 February 2018
Published online: 20 February 2018

References
1. Subramaniam T, Lennon P, O’Neill JP. Ongoing challenges in the treatment of adenoid cystic carcinoma of the head and neck. Ir J Med Sci. 2015;184(3):583–90. https://doi.org/10.1007/s11845-015-1298-1.
2. Kim DS, Sung JS, Shin ES, Ryu JS, Choi IK, Park KH, et al. Association of single nucleotide polymorphisms in PIM1 gene with the risk of Korean lung cancer. Cancer Res Treat. 2008;40(4):190–6. https://doi.org/10.4143/ct.2008.40.190.
3. Laurie SA, Ho AL, Fury MG, Sherman E, Pfister DG. Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review. Lancet Oncol. 2011;12(8):815–24. https://doi.org/10.1016/s1470-2245(10)70245-x.
4. Cuypers HT, Selten G, Quint W, Zijlstra M, Maandag ER, Boelens W, et al. Murine leukemia virus-induced T-cell lymphomagenesis: integration of proviruses in a distinct chromosomal region. Cell. 1984;37(1):141–50.
5. Zhang Y, Wang Z, Magnuson NS. PIM1 kinase-dependent phosphorylation of p21Cip1/WAF1 regulates its stability and cellular localization in H1299 cells. Mol Cancer Research. 2007;5(9):909–22. https://doi.org/10.1158/1541-7786.MCR-06-0388.
6. Liang C, Li YY. Use of regulators and inhibitors of PIM1, a serine/threonine kinase, for tumour therapy (review). Mol Med Rep. 2014;9(6):2051–60. https://doi.org/10.3892/mmr.2014.2139.
7. Bachmann M, Kosan C, Xing PX, Montenarh M, Hoffmann I, Moroy T. The oncogenic serine/threonine kinase PIM1 directly phosphorylates and activates the G2/M specific phosphatase Cdc2S5. Int J Biochem Cell Biol. 2006;38(3):430–43. https://doi.org/10.1016/j.biocell.2005.10.010.
8. Qian KC, Wang L, Hickey ER, Studts J, Barringer K, Peng C, et al. Structural basis of constitutive activity and a unique nucleotide binding mode of human PIM1 kinase. J Biol Chem. 2005;280(7):6130–7. https://doi.org/10.1074/jbc.M409132200.
9. Hoover D, Friedmann M, Reeves R, Magnuson NS. Recombinant human PIM1 protein exhibits serine/threonine kinase activity. J Biol Chem. 1991;266(21):14018–23.
10. Palaty CK, Clark-Lewis I, Leung D, Pelech SL. Phosphorylation site substate specificity determinants for the PIM1 protooncogene-encoded protein kinase. Biochem Cell Biol. 1997;75(2):153–62.
11. Wang Z, Bhattacharya N, Miiller PF, Wei W, Sedivy J, Magnuson NS. Phosphorylation of the cell cycle inhibitor p21Cip1/WAF1 by PIM1 kinase. Biochim Biophys Acta. 2002;1593(1):145–55.
12. Levenson JD, Koskinen PJ, Onisco FC, Rainio EM, Jalkanen KJ, Dash AB, et al. PIM1 kinase and p100 cooperate to enhance c-Myc activity. Mol Cell. 1998;2(4):417–25.
13. Mochizuki T, Kitanaka C, Noguchi K, Muramatsu T, Asai A, Kuchino Y. Physical and functional interactions between PIM1 kinase and Cdc25A phosphatase. Implications for the PIM1-mediated activation of the c-Myc signaling pathway. J Biol Chem. 1999;274(26):16956–66.
14. Koike N, Maita H, Taira T, Ariga H, Iguchi-Ariga SM. Identification of histone deacetylase 1 (HDAC1) as an interacting partner for PIM1 kinase and the effect of phosphorylation on the transcriptional repression function of HDAC1. J Biol Chem. 2000;275(16):1568–78.
15. Maita H, Harada Y, Nagakubo D, Kitaru H, Ikeda M, Tamai K, et al. PAP-1, a novel target protein of phosphorylation by PIM1 kinase. Eur J Biochem. 2000;267(16):1568–78.
16. Wang Z, Bhattacharya N, Meyer MK, Seimiya H, Tsuruo T, Tonani JA, et al. PIM1 negatively regulates the activity of PTP-152 phosphatase and influences terminal differentiation and apoptosis of monoblastoid leukemia cells. Arch Biochem Biophys. 2001;390(1):9–18. https://doi.org/10.1006/abbb.2001.2370.
17. Rainio EM, Sandholm J, Koskinen PJ. Cutting edge: transcriptional activity of NFATc1 is enhanced by the PIM1 kinase. J Immunol. 2002;168(4):1524–7.
18. Ishibashi Y, Maita H, Yano M, Koike N, Tamai K, Ariga H, et al. PIM1 translocates sorting nexin 6/TRAF4-associated factor 2 from cytoplasm to nucleus. FEBS Lett. 2001;506(1):52–8.
19. Bhattacharya N, Wang Z, Davitt C, McKenzie IF, Xing PX, Magnuson NS. PIM1 associates with protein complexes necessary for mitosis. Chromosoma. 2002;111(2):80–95. https://doi.org/10.1007/s00412-002-0192-6.
20. Shah N, Pang B, Yeoh KG, Thorn S, Chen CS, Lilly MB, et al. Potential roles for the PIM1 kinase in human cancer—a molecular and therapeutic appraisal. Eur J Cancer. 2008;44(15):2144–51. https://doi.org/10.1016/j.ejca.2008.06.044.
21. Kim J, Roh M, Abdulkadir SA. Pim1 promotes human prostate cancer cell tumorigenicity and c-MYC transcriptional activity. BMC Cancer. 2010;10:248. https://doi.org/10.1186/1471-2407-10-248.
22. Wang Z, Bhattacharya N, Weaver M, Petersen K, Meyer M, Gapter L, et al. PIM1: a serine/threonine kinase with a role in cell survival, proliferation, differentiation and tumorigenesis. J Vet Sci. 2002;3(2):167–79.
23. Waga S, Hannon GJ, Beach D, Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature. 1994;369(6481):574–8. https://doi.org/10.1038/369574a0.
24. Shijvi MK, Grey SJ, Straussfeld UP, Wood RD, Blow JJ. Cip1 inhibits DNA replication but not PCNA-dependent nucleotide excision-repair. Curr Biol. 1994;4(12):1062–8.
25. Ito Y. Oncogenic potential of the RUNX gene family: ‘overview’. Oncogene. 2004;23(24):4198–208. https://doi.org/10.1038/sj.onc.1207755.
26. He JF, Ge MH, Zhu X, Chen C, Tan Z, Li YN, et al. Expression of RUNX3 in salivary adenoid cystic carcinoma: implications for tumor progression and prognosis. Cancer Sci. 2008;99(7):1334–40. https://doi.org/10.1111/j.1349-7006.2008.00826.x.
27. Kim HR, Oh BC, Choi JK, Bae SC. PIM1 kinase phosphorylates and stabilizes RUNX3 and alters its subcellular localization. J Cell Biochem. 2008;105(4):1048–58. https://doi.org/10.1002/jcb.21906.
28. Chi XZ, Yang JQ, Lee KY, Ito K, Sakakura C, Li QL, et al. RUNX3 suppresses gastric epithelial cell growth by inducing p21 (WAF1/Cip1) expression in cooperation with transforming growth factor-β-activated SMAD. Mol Cell Biol. 2005;25(18):8097–107. https://doi.org/10.1128/mcb.25.18.8097-8107.2005.
29. Kim KT, Carroll AP, Mashkani B, Cairns MJ, Small D, Scott RJ. MicroRNA-16 is down-regulated in mutated FLT3 expressing murine myeloid FDC-P1 cells and interacts with PIM1. PLoS ONE. 2012;7(9):e44546. https://doi.org/10.1371/journal.pone.0044546.
30. Brault L, Gasser C, Bracher F, Huber K, Knapp S, Schwaller J. PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers. Haematologica. 2010;95(6):1004–15. https://doi.org/10.3324/haematol.2009.017079.
31. Magnuson NS, Wang Z, Ding G, Reeves R. Why target PIM1 for cancer diagnosis and treatment? Future Oncol. 2010;6(9):1461–78. https://doi.org/10.2217/фон.10.106.
32. Tong DD, Jiang Y, Li M, Kong D, Meng XN, Zhao YZ, et al. RUNX3 inhibits cell proliferation and induces apoptosis by TGF-β-dependent and -independent mechanisms in human colon carcinoma cells. Pathobiology. 2009;76(4):163–9. https://doi.org/10.1159/000218332.
33. Min B, Kim MK, Zhang JW, Kim J, Chung KC, Oh BC, et al. Identification of RUNX3 as a component of the MST/Hippo signaling pathway. J Cell Physiol. 2012;227(2):839–49. https://doi.org/10.1002/jcp.22887.
34. Aho TL, Sandholm J, Pentola KJ, Ito Y, Koskinen PJ. PIM1 kinase phosphorylates RUNX family transcription factors and enhances their activity. BMC Cell Biol. 2006;7:21. https://doi.org/10.1186/1471-2121-7-21.